MINERALYS THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
MINERALYS THERAPEUTICS, INC. (MLYS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$10.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.96M.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.95M, a 55.69% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.57M, a 150.05% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$3.56M.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.47M.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$4.93M, a 151.78% decline from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $9.53M, a 325.45% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.24M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$10.00K 10-Q · filed 2026-08-11 | -$1.58M derived: sum of 3 quarters · filed 2026-08-11 | -$5.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.95M 10-Q · filed 2026-05-06 | $380.00K derived: sum of 2 quarters · filed 2026-05-06 | -$3.18M derived: sum of 3 quarters · filed 2026-05-06 | -$4.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$5.13M derived: sum of 2 quarters · filed 2026-03-12 | -$6.87M derived: sum of 3 quarters · filed 2026-08-11 | -$2.47M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$5.30M derived: sum of 2 quarters · filed 2026-08-11 | -$902.00K 10-Q · filed 2025-11-10 | $2.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.66M 10-Q · filed 2026-08-11 | $5.79M derived: sum of 3 quarters · filed 2026-08-11 | $3.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $4.40M 10-Q · filed 2026-05-06 | $7.53M derived: sum of 2 quarters · filed 2026-05-06 | $4.80M derived: sum of 3 quarters · filed 2026-05-06 | $3.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $402.00K derived: sum of 2 quarters · filed 2026-03-12 | -$776.00K derived: sum of 3 quarters · filed 2026-03-12 | -$4.93M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$3.91M derived: sum of 2 quarters · filed 2025-11-10 | -$8.07M 10-Q · filed 2025-11-10 | -$6.85M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$5.34M 10-Q · filed 2025-08-12 | -$4.12M derived: sum of 3 quarters · filed 2025-08-12 | -$1.11M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$4.16M 10-Q · filed 2025-05-12 | -$2.94M derived: sum of 2 quarters · filed 2025-05-12 | $67.00K derived: sum of 3 quarters · filed 2025-05-12 | $3.67M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.23M derived: sum of 2 quarters · filed 2025-02-12 | $7.83M derived: sum of 3 quarters · filed 2025-02-12 | $9.53M 10-K · filed 2025-02-12 |
| 2023-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.61M derived: sum of 2 quarters · filed 2024-11-12 | $8.31M 10-Q · filed 2024-11-12 | $10.07M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $5.30M 10-Q · filed 2024-08-13 | $7.07M derived: sum of 3 quarters · filed 2024-08-13 | $7.60M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.70M 10-Q · filed 2024-05-09 | $3.47M derived: sum of 2 quarters · filed 2024-05-09 | $4.00M derived: sum of 3 quarters · filed 2024-05-09 | $4.05M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.30M derived: sum of 2 quarters · filed 2024-03-21 | $2.35M derived: sum of 3 quarters · filed 2024-03-21 | $2.24M 10-K · filed 2024-03-21 |
| 2022-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $581.00K derived: sum of 2 quarters · filed 2023-11-07 | $473.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$59.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$108.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |